Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.